DBV Technologies reported 461K in Interest Expense on Debt for its fiscal quarter ending in March of 2025.


Interest Expense On Debt Change Date
Acadia Pharmaceuticals 0 4.12M Sep/2024
Alnylam Pharmaceuticals USD 40.25M 1.6M Jun/2025
Amarin USD 3K 3K Dec/2024
BioMarin Pharmaceutical USD 2.68M 184K Jun/2025
DBV Technologies 461K 323.71K Mar/2025
Halozyme Therapeutics USD 4.39M 131K Jun/2025
Incyte USD 594K 66K Jun/2025
Insmed USD 21.24M 1.5M Jun/2025
Ionis Pharmaceuticals USD 19M 0 Jun/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
PTC Therapeutics USD 30.36M 4.03M Jun/2025
Sarepta Therapeutics USD 5.23M 725K Jun/2025
Ultragenyx Pharmaceutical 14.04M 1.48M Jun/2025
United Therapeutics USD 7.3M 1.2M Jun/2025